BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/15/2026 6:19:12 AM | Browse: 11 | Download: 44
 |
Received |
|
2025-10-09 01:43 |
|
Peer-Review Started |
|
2025-10-09 01:43 |
|
First Decision by Editorial Office Director |
|
2025-10-27 09:24 |
|
Return for Revision |
|
2025-10-27 09:24 |
|
Revised |
|
2025-11-09 11:08 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-02-03 02:34 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-02-03 09:02 |
|
Articles in Press |
|
2026-02-03 09:02 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-03-04 01:57 |
|
Publish the Manuscript Online |
|
2026-03-15 06:19 |
| ISSN |
2220-315x (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Neurosciences |
| Manuscript Type |
Editorial |
| Article Title |
DNA methylation profiling in central nervous system tumors: Where do we draw the line of clinical utility?
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Sumanta Das |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Sumanta Das, Assistant Professor, Department of Pathology, North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences, Gurugram, Shillong 793018, Meghālaya, India. sumantad755@gmail.com |
| Key Words |
DNA methylation profiling; Central nervous system tumors; Epigenetic classification; Prognostification; Diagnostic precision |
| Core Tip |
DNA methylation profiling has revolutionized central nervous system tumor classification by providing objective, reproducible, and prognostically relevant molecular signatures. However, its integration into routine neuropathology practice requires judicious application. This editorial highlights the need to balance diagnostic precision with practical limitations such as cost, accessibility, and turnaround time. We emphasize that methylation profiling should complement, not replace, conventional histopathology, immunohistochemistry, and targeted molecular assays, reserved for diagnostically ambiguous or high-impact cases where it can meaningfully influence patient management. |
| Publish Date |
2026-03-15 06:19 |
| Citation |
Das S. DNA methylation profiling in central nervous system tumors: Where do we draw the line of clinical utility? World J Exp Med 2026; 16(1): 115070 |
| URL |
https://www.wjgnet.com/2220-315x/full/v16/i1/115070.htm |
| DOI |
https://dx.doi.org/10.5493/wjem.v16.i1.115070 |
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
